1121 related articles for article (PubMed ID: 23989056)
1. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review.
Tamura K; Ohtsuka T; Ideno N; Aso T; Shindo K; Aishima S; Ohuchida K; Takahata S; Ushijima Y; Ito T; Oda Y; Mizumoto K; Tanaka M
Ann Surg; 2014 Feb; 259(2):360-8. PubMed ID: 23989056
[TBL] [Abstract][Full Text] [Related]
2. Assessment of clonality of multisegmental main duct intraductal papillary mucinous neoplasms of the pancreas based on GNAS mutation analysis.
Tamura K; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Ideno N; Aso T; Miyazaki T; Ohuchida K; Takahata S; Ito T; Ushijima Y; Oda Y; Mizumoto K; Tanaka M
Surgery; 2015 Feb; 157(2):277-84. PubMed ID: 25530484
[TBL] [Abstract][Full Text] [Related]
3. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
[TBL] [Abstract][Full Text] [Related]
4. Follow-up study after resection of intraductal papillary mucinous neoplasm of the pancreas; special references to the multifocal lesions and development of ductal carcinoma in the remnant pancreas.
Ohtsuka T; Kono H; Tanabe R; Nagayoshi Y; Mori Y; Sadakari Y; Takahata S; Oda Y; Aishima S; Igarashi H; Ito T; Ishigami K; Nakamura M; Mizumoto K; Tanaka M
Am J Surg; 2012 Jul; 204(1):44-8. PubMed ID: 21996346
[TBL] [Abstract][Full Text] [Related]
5. Oncocytic-type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis.
Marchegiani G; Mino-Kenudson M; Ferrone CR; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
J Am Coll Surg; 2015 May; 220(5):839-44. PubMed ID: 25840549
[TBL] [Abstract][Full Text] [Related]
6. Molecular Evidence for Monoclonal Skip Progression in Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Date K; Ohtsuka T; Fujimoto T; Tamura K; Kimura H; Matsunaga T; Mochidome N; Miyazaki T; Mori Y; Oda Y; Nakamura M; Tanaka M
Ann Surg; 2017 May; 265(5):969-977. PubMed ID: 28398963
[TBL] [Abstract][Full Text] [Related]
7. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
[TBL] [Abstract][Full Text] [Related]
8. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
[TBL] [Abstract][Full Text] [Related]
9. GNAS but Not Extended RAS Mutations Spectrum are Associated with a Better Prognosis in Intraductal Pancreatic Mucinous Neoplasms.
Gaujoux S; Parvanescu A; Cesaretti M; Silve C; Bieche I; Rebours V; Lévy P; Sauvanet A; Cros J
Ann Surg Oncol; 2019 Aug; 26(8):2640-2650. PubMed ID: 31025231
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M
Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586
[TBL] [Abstract][Full Text] [Related]
11. Long-term surveillance is necessary after operative resection for intraductal papillary mucinous neoplasm of the pancreas.
Hirono S; Kawai M; Okada K; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yanagisawa A; Yamaue H
Surgery; 2016 Aug; 160(2):306-17. PubMed ID: 27236360
[TBL] [Abstract][Full Text] [Related]
12. GNAS and KRAS mutational analyses of intraductal papillary neoplasms of the pancreas and bile duct developing in the same individual: A case report.
Date K; Ohtsuka T; Fujimoto T; Gotoh Y; Nakashima Y; Kimura H; Matsunaga T; Mori Y; Mochidome N; Miyazaki T; Oda Y; Tanaka M; Nakamura M
Pancreatology; 2015; 15(6):713-6. PubMed ID: 26506885
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas.
Matthaei H; Norris AL; Tsiatis AC; Olino K; Hong SM; dal Molin M; Goggins MG; Canto M; Horton KM; Jackson KD; Capelli P; Zamboni G; Bortesi L; Furukawa T; Egawa S; Ishida M; Ottomo S; Unno M; Motoi F; Wolfgang CL; Edil BH; Cameron JL; Eshleman JR; Schulick RD; Maitra A; Hruban RH
Ann Surg; 2012 Feb; 255(2):326-33. PubMed ID: 22167000
[TBL] [Abstract][Full Text] [Related]
14. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
[TBL] [Abstract][Full Text] [Related]
15. Predictive Factors for the Metachronous Development of High-risk Lesions in the Remnant Pancreas After Partial Pancreatectomy for Intraductal Papillary Mucinous Neoplasm.
Miyasaka Y; Ohtsuka T; Tamura K; Mori Y; Shindo K; Yamada D; Takahata S; Ishigami K; Ito T; Tokunaga S; Oda Y; Mizumoto K; Nakamura M; Tanaka M
Ann Surg; 2016 Jun; 263(6):1180-7. PubMed ID: 26334637
[TBL] [Abstract][Full Text] [Related]
16. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts.
Singhi AD; Nikiforova MN; Fasanella KE; McGrath KM; Pai RK; Ohori NP; Bartholow TL; Brand RE; Chennat JS; Lu X; Papachristou GI; Slivka A; Zeh HJ; Zureikat AH; Lee KK; Tsung A; Mantha GS; Khalid A
Clin Cancer Res; 2014 Aug; 20(16):4381-9. PubMed ID: 24938521
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Recurrence After Resection of IPMN: Who, When, and How?
Marchegiani G; Mino-Kenudson M; Ferrone CR; Morales-Oyarvide V; Warshaw AL; Lillemoe KD; Castillo CF
Ann Surg; 2015 Dec; 262(6):1108-14. PubMed ID: 25793719
[TBL] [Abstract][Full Text] [Related]
18. Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas.
Pea A; Yu J; Rezaee N; Luchini C; He J; Dal Molin M; Griffin JF; Fedor H; Fesharakizadeh S; Salvia R; Weiss MJ; Bassi C; Cameron JL; Zheng L; Scarpa A; Hruban RH; Lennon AM; Goggins M; Wolfgang CL; Wood LD
Ann Surg; 2017 Jul; 266(1):133-141. PubMed ID: 27433916
[TBL] [Abstract][Full Text] [Related]
19. A large multicenter study of recurrence after surgical resection of branch-duct intraductal papillary mucinous neoplasm of the pancreas.
Yan L; Siddiqui AA; Laique SN; Saumoy M; Kahaleh M; Yoo J; Kalra A; Mathew A; Sterling J; Rao R; Lieberman M; Cosgrove N; Sharaiha RZ
Minerva Gastroenterol Dietol; 2017 Mar; 63(1):50-54. PubMed ID: 27824244
[TBL] [Abstract][Full Text] [Related]
20. Inferior head resection of the pancreas for intraductal papillary mucinous neoplasms.
Nakagohri T; Kinoshita T; Konishi M; Takahashi S; Gotohda N; Kobayashi S; Kojima M; Miyauchi H; Asano T
J Hepatobiliary Pancreat Sci; 2010 Nov; 17(6):798-802. PubMed ID: 19727540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
